Malabsorption News

WASHINGTON — AMG 715, an investigational anti-interleukin 15 inhibitor, showed safety and efficacy for stopping the progression of refractory celiac disease type II, according to phase 2 randomized controlled trial data presented at DDW 2018.

WASHINGTON — In this exclusive video, Joseph Murray, MD, of the Mayo Clinic in Rochester, Minn., shares an overview of key research and discussions in celiac disease being shared at Digestive Disease Week.

An experimental biologic drug showed promise for reducing symptoms and inflammation in patients with celiac disease following gluten exposure, according to data from a phase 2 proof-of-concept study released in advance of DDW 2018.

Two hospitals with ties to the Harvard Medical School Celiac Research Program will investigate an at-home test called Gluten Detective designed to monitor gluten consumption in people on a gluten-free diet.

Heath Canada granted a medical device establishment license to Commonwealth Diagnostics International for their noninvasive tests for irritable bowel syndrome and other functional GI disorders like small intestine bacterial overgrowth and carbohydrate malabsorption disorders, the company announced.

RP-G28, a novel prebiotic in development for the treatment of lactose intolerance has the potential to become the first FDA-approved treatment for lactose intolerance, a condition that affects millions of Americans, according to the developer Ritter Pharmaceuticals.

Patients who experience gastrointestinal symptoms like abdominal pain and diarrhea after consuming sugary foods and drinks could have a genetic condition called genetic sucrase-isomaltase deficiency, which prevents them from properly digesting common table sugar.

Anthera Pharmaceuticals announced it will discontinue the development of Sollpura after the drug failed to meet the primary endpoint of a phase 3 trial.

Patients with celiac disease can have their diagnosis delayed by about 3.5 years if they do not have gastrointestinal symptoms, according to research published in The American Journal of Medicine.

True Health has announced that it will offer new comprehensive testing for celiac disease and gluten sensitivity.